Is Your Patient with Uncontrolled Severe Asthma Not Responding to a Biologic?

Affiliations

¹ Division of Pulmonary and Critical Care, Washington University in St Louis, St. Louis, Mo.
² Division of Pulmonary and Critical Care, Washington University in St Louis, St. Louis, Mo. Electronic address: castrom@wustl.edu.

Editorial

Maanasi Samant et al. J Allergy Clin Immunol Pract. 2019 Sep-Oct.

. 2019 Sep-Oct;7(7):2284-2285.

doi: 10.1016/j.jaip.2019.05.021.

¹ Division of Pulmonary and Critical Care, Washington University in St Louis, St. Louis, Mo.
² Division of Pulmonary and Critical Care, Washington University in St Louis, St. Louis, Mo. Electronic address: castrom@wustl.edu.

No abstract available

Comment on

Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
Pérez de Llano LA, Cosío BG, Domingo C, Urrutia I, Bobolea I, Valero A, Entrenas Costa LM, Quirce S, Barranco P, Marina Malanda N, Andrés LP, Alvarez-Gutiérrez FJ. Pérez de Llano LA, et al. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2277-2283.e2. doi: 10.1016/j.jaip.2019.01.017. Epub 2019 Jan 21. J Allergy Clin Immunol Pract. 2019. PMID: 30677539 Clinical Trial.